Sangamo BioSciences Inc. (NASDAQ:SGMO)’s share price dropped 1.5% during mid-day trading on Monday . The stock traded as low as $6.04 and last traded at $6.09, with a volume of 342,921 shares traded. The stock had previously closed at $6.18.

SGMO has been the subject of several recent analyst reports. Jefferies Group reaffirmed a “buy” rating and issued a $14.00 price target on shares of Sangamo BioSciences in a research report on Thursday, June 9th. Zacks Investment Research lowered Sangamo BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Wells Fargo & Co. started coverage on Sangamo BioSciences in a research report on Tuesday, May 3rd. They issued a “buy” rating for the company. Finally, Wedbush reissued an “outperform” rating and issued a $30.00 target price on shares of Sangamo BioSciences in a research report on Friday, May 6th. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Sangamo BioSciences presently has a consensus rating of “Buy” and a consensus price target of $16.75.

The stock’s 50 day moving average price is $6.24 and its 200-day moving average price is $6.28. The stock’s market capitalization is $413.79 million.

Sangamo BioSciences (NASDAQ:SGMO) last issued its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The company had revenue of $3.94 million for the quarter, compared to the consensus estimate of $5.49 million. Sangamo BioSciences’s revenue for the quarter was down 70.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.08) EPS. Analysts anticipate that Sangamo BioSciences Inc. will post ($0.98) earnings per share for the current year.

A number of large investors recently modified their holdings of the stock. Numeric Investors LLC increased its stake in shares of Sangamo BioSciences by 80.7% in the fourth quarter. Numeric Investors LLC now owns 148,969 shares of the biopharmaceutical company’s stock worth $1,360,000 after buying an additional 66,519 shares during the last quarter. California State Teachers Retirement System increased its stake in shares of Sangamo BioSciences by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 128,941 shares of the biopharmaceutical company’s stock worth $1,177,000 after buying an additional 2,257 shares during the last quarter. Finally, Royce & Associates LLC increased its stake in shares of Sangamo BioSciences by 47.1% in the fourth quarter. Royce & Associates LLC now owns 312,100 shares of the biopharmaceutical company’s stock worth $2,849,000 after buying an additional 100,000 shares during the last quarter.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.